Milrinone During Living Donor Hepatectomy

Seoul National University Hospital38 enrolled

Overview

Maintaining a low central venous pressure during living donor hepatectomy is routine practice. The investigators tried to test the hypothesis that using milrinone to maintain a low central venous pressure (CVP) during is associated with a superior surgical field and less blood loss.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

TRIPLE

Enrollment

Conditions

Hepatectomy

Interventions

milrinoneDRUG

placeboDRUG

Eligibility

Sex: ALLMin age: 19 YearsMax age: 55 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Living liver donors Exclusion Criteria: * Donors with concurrent cardiac, pulmonary, and urologic disease * Hepatectomy performed laparoscopically

Locations (1)

Seoul National University Hospital

Seoul, South Korea

Outcomes

Primary Outcomes

condition of surgical field

Time frame: intraoperative period (from the start of surgery to end of living donor hepatectomy)

Secondary Outcomes

the use of vasopressor and diuretics to maintain hemodynamic stability and low CVP status, respectively

Time frame: intraoperative period (from the start of surgery to end of living donor hepatectomy)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.